CAS: 32281-97-3; 7-Bromo-3,4-Dihydronaphthalen-1(2H)-One

上下游产品

CAS号529-34-0 1-四氢萘酮 | CAS号35656-89-4 4-溴苯丁酸 | CAS号75693-15-1 7-溴-1,2,3,4-四氢萘-1-酚 | CAS号6340-79-0 3-(4-溴苯甲酰)丙酸 | CAS号6628-03-1 4-(4-bromopheny... | CAS号108-86-1 溴苯 | CAS号111773-13-8 7-Bromo-1,2,3,4... | CAS号6134-56-1 6-溴-1,2,3,4-四氢-萘 | CAS号283177-40-2 7-溴-1-氯-3,4-二氢萘-2-甲醛 | CAS号2717-47-7 1,2-Dihydro-6-m... | CAS号2965-43-7 Benzoic acid,2-... | CAS号319-04-0 7-溴-1-氟萘 | CAS号33295-35-1 7-溴-1-甲基萘 | CAS号3109-50-0 Benzoic acid,2-... | CAS号137466-19-4 N-(9-fluoro-2,3... | CAS号116047-27-9 2-benzylidene-7...

3-(4-溴苯甲酰)丙酸置于polyphosphoric Acid体系中,化学反应 3.0H,反应生成 7-溴-3,4-二氢萘-1(2H)-酮
参考文献:可见光诱导的氧化/ [3 + 2]环加成/氧化芳构化由1,2,3,4-四氢萘和芳基肼盐酸盐构建苯并[a]咔唑.
标题:可见光诱导的氧化/ [3 + 2]环加成/氧化芳构化由1,2,3,4-四氢萘和芳基肼盐酸盐构建苯并[a]咔唑.
摘要:据报道,通过可见光串联氧化/ [3 + 2]环加成/氧化芳构化反应可有效合成苯并[a]咔唑.四氢萘的苄基c(sp3)-H通过可见光的光氧化还原催化剂在温和的反应条件下用氧气作为清洁氧化剂进行活化.该协议在广泛的底物范围内有效进行,并进行了机理研究.
DOI:10.1021/acs.Orglett.9B02939

专利信息

专利号:US-4374979-A
优先权日:1981-04-27
标 题:Regiospecific synthesis of anthracyclinone compounds such as daunomycinone
发明人：MITSCHER LESTER A
权利人:UNIV KANSAS ENDOWMENT ASS
摘要:A regiospecific synthesis for anthracyclinones asymmetric is disclosed. The synthesis is based upon a regiospecific bromination of the C-7 position of the alpha -tetralone which after transposing the keto group to the beta -position and reaction with an organo-lithium compound is condensed with a phthalate ester.

专利号:US-4777257-A
优先权日:1983-08-25
标题:Certain tetrahydronaphthyl or indanylcarboxylates and derivatives thereof which inhibit the synthesis of thromboxane
发明人：KANAO MUNEFUMI
权利人:DAIICHI SEIYAKU CO
摘要:Benzocycloalkane derivatives of the formula (I) ##STR1## wherein: Z represents a methylene group or an ethylene group, either one of R 1 and R 2 represents --(CH 2 ) m --COOR 3 and the other represents ##STR2## wherein R 3 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, n represents an interger of 1 to 6 and m represents an interger of 0 to 5, and the physiologically acceptable salts thereof; having a strong and selective inhibition activity of thromboxane A 2 synthesis.

专利号:US-6090810-A
优先权日:1995-09-01
标题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-5877207-A
优先权日:1996-03-11
标 题:Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN SALES INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-2003219832-A1
优先权日:1996-03-11
标 题 :Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
发明人：KLEIN ELLIOTT S; STANDEVEN ANDREW M; NAGPAL SUNIL; CHANDRARATNA ROSHANTHA A
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.

专利号:US-6469028-B1
优先权日:1995-09-01
标题:Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities
发明人：KLEIN ELLIOTT S; JOHNSON ALAN T; STANDEVEN ANDREW M; BEARD RICHARD L; GILLETT SAMUEL J; DUONG TIEN T; NAGPAL SUNIL; VULIGONDA VIDYASAGAR; TENG MIN; CHANDRARATNA ROSHANTHA A
权利人:ALLERGAN INC
摘要:Aryl-substituted and aryl and (3-oxo-1-propenly)-substituted benzopyran, benzothiopyran, 1,2-dihydroquinoline, and 5,6-dihydronaphthalene derivatives have retinoid negative hormone and/or antagonist-like biological activities. The invented RAR antagonists can be administered to mammals, including humans, for the purpose of preventing or diminishing action of RAR agonists on the bound receptor sites. Specifically, the RAR agonists are administered or coadministered with retinoid drugs to prevent or ameliorate toxicity or side effects caused by retinoids or vitamin A or vitamin A precursors. The retinoid negative hormones can be used to potentiate the activities of other retinoids and nuclear receptor agonists. For example, the retinoid negative hormone called AGN 193109 effectively increased the effectiveness of other retinoids and steroid hormones in in vitro transactivation assays. Additionally, transactivation assays can be used to identify compounds having negative hormone activity. These assays are based on the ability of negative hormones to down-regulate the activity of chimeric retinoid receptors engineered to possess a constitutive transcription activator domain.